AtaiBeckley Inc. - Common Stock (NQ:ATAI)

3.350 -0.190 (-5.37%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Price and Volume

Volume	3,254,138
Open	3.620
Bid (Size)	3.390 (200)
Ask (Size)	3.520 (400)
Prev. Close	3.540
Today's Range	3.315 - 3.660
52wk Range	1.150 - 6.750
Shares Outstanding	166,010,476
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics

March 26, 2026

Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more...

Via Finterra

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

March 24, 2026

From AtaiBeckley Inc.

Via GlobeNewswire

Performance

YTD	-13.4%	-13.4%
1 Month	-22.8%	-22.8%
3 Month	-17.7%	-17.7%
6 Month	-36.4%	-36.4%
1 Year	+113.4%	+113.4%

More News

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

March 17, 2026

From AtaiBeckley Inc.

Via GlobeNewswire

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

March 10, 2026

From AtaiBeckley Inc.

Via GlobeNewswire

ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!

March 09, 2026

Via AB Newswire

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

March 06, 2026

From AtaiBeckley Inc.

Via GlobeNewswire

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

March 03, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

February 26, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

February 20, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

February 19, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley To Participate in Upcoming Investor Conferences

February 17, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗

January 19, 2026

Via MarketBeat

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

January 16, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

January 08, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗

January 05, 2026

Via Stocktwits

AtaiBeckley Completes Redomiciliation to the United States

December 30, 2025

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

December 23, 2025

From AtaiBeckley N.V.

Via GlobeNewswire

MarketBeat’s Top 5 Rated Small-Cap Stocks ↗

December 22, 2025

Via MarketBeat

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗

December 19, 2025

Via Stocktwits

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio

December 11, 2025

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London

November 13, 2025

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 12, 2025

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

November 10, 2025

From AtaiBeckley N.V.

Via GlobeNewswire

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies

November 05, 2025

From AtaiBeckley N.V.

Via GlobeNewswire

Analyst Expectations For ATAI Life Sciences's Future ↗

October 22, 2025

Via Benzinga

Frequently Asked Questions

Is AtaiBeckley Inc. - Common Stock publicly traded?

Yes, AtaiBeckley Inc. - Common Stock is publicly traded.

What exchange does AtaiBeckley Inc. - Common Stock trade on?

AtaiBeckley Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for AtaiBeckley Inc. - Common Stock?

The ticker symbol for AtaiBeckley Inc. - Common Stock is ATAI on the Nasdaq Stock Market

What is the current price of AtaiBeckley Inc. - Common Stock?

The current price of AtaiBeckley Inc. - Common Stock is 3.350

When was AtaiBeckley Inc. - Common Stock last traded?

The last trade of AtaiBeckley Inc. - Common Stock was at 03/27/26 04:00 PM ET

What is the market capitalization of AtaiBeckley Inc. - Common Stock?

The market capitalization of AtaiBeckley Inc. - Common Stock is 556.14M

How many shares of AtaiBeckley Inc. - Common Stock are outstanding?

AtaiBeckley Inc. - Common Stock has 556M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.